amantadine indications/contra

Stem definitionDrug idCAS RN
adamantane derivatives 144 768-94-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • amantadine
  • adamantamine
  • adamantanamine
  • adamantylamine
  • amantadine hydrochloride
  • amantidine
  • adamantamine fumarate
  • amantadine HCl
  • amantadine sulfate
An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.
  • Molecular weight: 151.25
  • Formula: C10H17N
  • CLOGP: 2
  • LIPINSKI: 0
  • HAC: 1
  • HDO: 1
  • TPSA: 26.02
  • ALOGS: -3.25
  • ROTB: 0

Drug dosage:

DoseUnitRoute
0.20 g O

Approvals:

DateAgencyCompanyOrphan
Feb. 14, 1968 FDA ENDO PHARMS

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination, visual 295.90 40.08 58 632 4418 3380751
Dyskinesia 250.84 40.08 55 635 7230 3377939
Completed suicide 209.73 40.08 64 626 31050 3354119
Hallucination 183.29 40.08 48 642 13292 3371877
On and off phenomenon 171.84 40.08 24 666 206 3384963
Toxicity to various agents 145.63 40.08 54 636 47000 3338169
Tremor 143.78 40.08 47 643 28097 3357072
Delirium 143.40 40.08 37 653 9591 3375578
Corneal oedema 141.42 40.08 23 667 583 3384586
Serotonin syndrome 137.54 40.08 32 658 5391 3379778
Confusional state 129.95 40.08 47 643 37951 3347218
Fall 123.48 40.08 51 639 58832 3326337
Agitation 113.02 40.08 36 654 19670 3365499
Myoclonus 109.49 40.08 25 665 3858 3381311
Neuroleptic malignant syndrome 106.15 40.08 25 665 4416 3380753
Impulse-control disorder 105.06 40.08 17 673 415 3384754
Delusion 95.50 40.08 22 668 3523 3381646
Parkinson's disease 82.47 40.08 18 672 2253 3382916
Disorientation 77.03 40.08 23 667 10056 3375113
Mental status changes 76.88 40.08 23 667 10124 3375045
Hypersexuality 76.20 40.08 13 677 440 3384729
Dopamine dysregulation syndrome 73.93 40.08 11 679 151 3385018
Soft tissue mass 72.24 40.08 10 680 79 3385090
Muscle rigidity 72.01 40.08 17 673 3017 3382152
Illusion 71.96 40.08 12 678 353 3384816
Seizure 64.52 40.08 29 661 40371 3344798
Depressed mood 63.28 40.08 18 672 6623 3378546
Psychotic disorder 62.69 40.08 19 671 8715 3376454
Gambling disorder 60.93 40.08 11 679 518 3384651
Loss of consciousness 60.68 40.08 25 665 28122 3357047

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC N04BB01 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Adamantane derivatives
CHEBI has role CHEBI:36044 antiviral drug
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:48560 dopaminergic agent
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35481 non-narcotic analgesic
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
FDA EPC N0000175543 Influenza A M2 Protein Inhibitor
FDA MoA N0000175542 M2 Protein Inhibitors

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Postencephalitic parkinsonism indication 19972008 DOID:14332
Parkinsonism indication 32798002 DOID:13548
Parkinson's disease indication 49049000 DOID:14330
Extrapyramidal disease indication 76349003
Influenza due to Influenza A virus indication 442438000
Influenza A Prevention indication
Arteriosclerotic Parkinsonism indication
Suicidal thoughts contraindication 6471006
Orthostatic hypotension contraindication 28651003
Eczema contraindication 43116000 DOID:2723
Chronic heart failure contraindication 48447003
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Epilepsy contraindication 84757009 DOID:1826
Kidney disease contraindication 90708001 DOID:2527
Edema contraindication 267038008
Malignant melanoma contraindication 372244006 DOID:1909
Angle-closure glaucoma contraindication 392291006 DOID:13550
Psychiatric Disturbance contraindication
Jakob-Creutzfeldt disease off-label use 792004 DOID:11949
Cognitive Impairment following Traumatic Brain Injury off-label use
Fatigue due to Multiple Sclerosis off-label use

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.4 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 137MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 8796337 Nov. 23, 2025 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 137MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 8895615 Nov. 23, 2025 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 137MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 8895616 Nov. 23, 2025 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 137MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 8895617 Nov. 23, 2025 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 68.5MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 8796337 Nov. 23, 2025 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 68.5MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 8895615 Nov. 23, 2025 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 68.5MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 8895616 Nov. 23, 2025 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 68.5MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 8895617 Nov. 23, 2025 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 129MG BASE OSMOLEX ER OSMOTICA PHARM N209410 Feb. 16, 2018 RX TABLET, EXTENDED RELEASE ORAL 8574626 Nov. 28, 2025 A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
EQ 193MG BASE OSMOLEX ER OSMOTICA PHARM N209410 Feb. 16, 2018 RX TABLET, EXTENDED RELEASE ORAL 8574626 Nov. 28, 2025 A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
EQ 258MG BASE OSMOLEX ER OSMOTICA PHARM N209410 Feb. 16, 2018 RX TABLET, EXTENDED RELEASE ORAL 8574626 Nov. 28, 2025 A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT
EQ 137MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 8389578 Jan. 22, 2028 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING IMMEDIATE RELEASE LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 68.5MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 8389578 Jan. 22, 2028 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING IMMEDIATE RELEASE LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 137MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 8741343 Dec. 2, 2030 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 137MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9867791 Dec. 2, 2030 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 137MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9867792 Dec. 2, 2030 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 137MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9867793 Dec. 2, 2030 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 137MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9877933 Dec. 2, 2030 TREATMENT OF DYSKINESIA AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 68.5MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 8741343 Dec. 2, 2030 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 68.5MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9867791 Dec. 2, 2030 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 68.5MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9867792 Dec. 2, 2030 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 68.5MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9867793 Dec. 2, 2030 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS
EQ 68.5MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL 9877933 Dec. 2, 2030 TREATMENT OF DYSKINESIA AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS

Orange Book exclusivity data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 137MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL Aug. 24, 2020 NEW PRODUCT
EQ 68.5MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL Aug. 24, 2020 NEW PRODUCT
EQ 137MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL Aug. 24, 2024 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY WITH OR WITHOUT CONCOMITANT DOPMINERGIC MEDICATIONS
EQ 68.5MG BASE GOCOVRI ADAMAS PHARMA N208944 Aug. 24, 2017 RX CAPSULE, EXTENDED RELEASE ORAL Aug. 24, 2024 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY WITH OR WITHOUT CONCOMITANT DOPMINERGIC MEDICATIONS

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glutamate [NMDA] receptor Ion channel BLOCKER Ki 4.98 CHEMBL CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.69 CHEMBL
Multidrug and toxin extrusion protein 1 Transporter IC50 4.42 CHEMBL
Matrix protein 2 Ion channel INHIBITOR IC50 4.80 CHEMBL CHEMBL
Matrix protein 2 Unclassified IC50 4.80 CHEMBL

External reference:

scroll-->
IDSource
CHEBI:2618 CHEBI
4019601 VUID
N0000147697 NUI
C0002403 UMLSCUI
4128 IUPHAR_LIGAND_ID
D00777 KEGG_DRUG
CHEMBL660 ChEMBL_ID
DB00915 DRUGBANK_ID
620 RXNORM
372763006 SNOMEDCT_US
51361008 SNOMEDCT_US
4161 MMSL
d00086 MMSL
4019601 VANDF
N0000006670 NDFRT
N0000147697 NDFRT
004663 NDDF
9921T5P019 UNII
31377-23-8 SECONDARY_CAS_RN
CHEMBL1569 ChEMBL_ID
CHEMBL465617 ChEMBL_ID
1816 INN_ID
D000547 MESH_DESCRIPTOR_UI
2130 PUBCHEM_CID
308 PDB_CHEM_ID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
AMANTADINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0121-0646 SOLUTION 50 mg ORAL ANDA 13 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1704 CAPSULE 100 mg ORAL ANDA 12 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1868 CAPSULE 100 mg ORAL ANDA 12 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-4920 TABLET 100 mg ORAL ANDA 12 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-4930 CAPSULE 100 mg ORAL ANDA 13 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0615-0326 CAPSULE 100 mg ORAL ANDA 13 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-2048 CAPSULE 100 mg ORAL ANDA 13 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-0111 TABLET 100 mg ORAL ANDA 13 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-1015 CAPSULE, GELATIN COATED 100 mg ORAL ANDA 14 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0832-2012 CAPSULE 100 mg ORAL ANDA 13 sections
amantadine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6630 CAPSULE 100 mg ORAL ANDA 12 sections
Amantadine HCl HUMAN PRESCRIPTION DRUG LABEL 1 10888-5006 CAPSULE, LIQUID FILLED 100 mg ORAL ANDA 12 sections
Gapeam Budibac HUMAN PRESCRIPTION DRUG LABEL 7 15455-0717 KIT 1 g TOPICAL unapproved drug other 5 sections
AMANTADINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-008 CAPSULE 100 mg ORAL ANDA 13 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-0093 SOLUTION 50 mg ORAL ANDA 13 sections
Amantadine HCl HUMAN PRESCRIPTION DRUG LABEL 1 21695-564 CAPSULE 100 mg ORAL ANDA 11 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 23155-362 CAPSULE 100 mg ORAL ANDA 11 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 33261-773 CAPSULE 100 mg ORAL ANDA 13 sections
Amantadine HCl HUMAN PRESCRIPTION DRUG LABEL 1 42291-125 CAPSULE, LIQUID FILLED 100 mg ORAL ANDA 12 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42543-493 CAPSULE 100 mg ORAL ANDA 12 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 42543-497 TABLET 100 mg ORAL ANDA 12 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 43353-947 CAPSULE 100 mg ORAL ANDA 13 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 46287-015 SOLUTION 50 mg ORAL ANDA 13 sections
amantadine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 46672-606 SYRUP 50 mg ORAL ANDA 13 sections
amantadine HUMAN PRESCRIPTION DRUG LABEL 1 46708-246 CAPSULE 100 mg ORAL ANDA 12 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 49999-324 CAPSULE 100 mg ORAL ANDA 13 sections
Amantadine HCl HUMAN PRESCRIPTION DRUG LABEL 1 50268-069 CAPSULE, LIQUID FILLED 100 mg ORAL ANDA 12 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 50383-807 SOLUTION 50 mg ORAL ANDA 12 sections
Amantadine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 51079-247 CAPSULE 100 mg ORAL ANDA 13 sections
Amantadine HCl HUMAN PRESCRIPTION DRUG LABEL 1 53808-0933 CAPSULE, LIQUID FILLED 100 mg ORAL ANDA 12 sections